CAS 2101765-81-3

Fórmula: C32H24N2O7S

InChI: InChI=1S/C32H24N2O7S/c1-41-32(37)25-14-12-23(13-15-25)30(35)33-26-18-16-21(17-19-26)20-8-10-24(11-9-20)31(36)34-27-6-2-4-22-5-3-7-28(29(22)27)42(38,39)40/h2-19H,1H3,(H,33,35)(H,34,36)(H,38,39,40)

Clave InChI: BZAWLSZPOBGURT-UHFFFAOYSA-N

SMILES: COC(=O)C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4=CC=CC5=C4C(=CC=C5)S(=O)(=O)O

DRI-C21045

CAS: 2101765-81-3

DRI-C21045

Fórmula: C₃₂H₂₄N₂O₇S

Pureza: ≥95%

Peso molecular: 580.61

Ref: 54-BUP06662

DRI-C21045

CAS: 2101765-81-3

Dri-c21045 inhibits NF-kB (IC50=17.1μM) and B cell proliferation (IC50=4.5μM), selectively blocking CD40-CD40L interaction (IC50=0.17μM).

Fórmula: C₃₂H₂₄N₂O₇S

Pureza: 97.20%

Forma y color: Solid

Peso molecular: 580.607

Ref: TM-T11096

DRI-C20145

CAS: 2101765-81-3

Fórmula: C₃₂H₂₄N₂O₇S

Pureza: 97.20%

Forma y color: Solid

Peso molecular: 580.6072

Ref: IN-DA01MVPU

DRI-c21045

CAS: 2101765-81-3

DRI-c21045 is an analog of a medicinal compound that has been shown to inhibit the activity of a specific protein kinase involved in cell cycle regulation and tumor growth. This inhibitor has been demonstrated to induce apoptosis in cancer cells, making it a promising candidate for anticancer therapy. DRI-c21045 has been tested in both Chinese and human cancer cell lines and has shown potent activity against various types of tumors. Additionally, this compound has been detected in urine samples from patients with cancer, suggesting that it may have potential as a diagnostic marker for certain types of cancer. Overall, DRI-c21045 shows great promise as a potential anticancer agent with significant therapeutic potential.

Fórmula: C₃₂H₂₄N₂O₇S

Pureza: Min. 95%

Peso molecular: 580.6 g/mol

Ref: 3D-BJD76581